Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. vinorelbine pierre fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

Belgicko - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - vinorelbine tartrate 13,85 mg/ml - eq. vinorelbine 10 mg/ml - concentrate for solution for infusion - 10 mg/ml - vinorelbine tartrate 13.85 mg/ml - vinorelbine

Belgicko - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - vinorelbine tartrate 13,85 mg/ml - eq. vinorelbine 10 mg/ml - concentrate for solution for infusion - 10 mg/ml - vinorelbine tartrate 13.85 mg/ml - vinorelbine

Belgicko - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - vinorelbine tartrate 13,85 mg/ml - eq. vinorelbine 10 mg/ml - concentrate for solution for infusion - 10 mg/ml - vinorelbine tartrate 13.85 mg/ml - vinorelbine

Belgicko - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - vinorelbine tartrate 13,85 mg/ml - eq. vinorelbine 10 mg/ml - concentrate for solution for infusion - 10 mg/ml - vinorelbine tartrate 13.85 mg/ml - vinorelbine

Kanada - angličtina - Health Canada

fresenius kabi canada ltd - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty limited - vinorelbine tartrate -

Namíbia - angličtina - Namibia Medicines Regulatory Council

teva pharmaceuticals (pty) ltd - vinorelbine tartrate - injection - each 1 ml vial contains; vinorelbine tartrate equivalent to vinorelbine 10,0 mg

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - vinorelbine tartrate 13.85mg equivalent to to 10 mg vinorelbine - concentrate for injection - 10 mg/ml - active: vinorelbine tartrate 13.85mg equivalent to to 10 mg vinorelbine excipient: nitrogen water for injection - dbl™ vinorelbine injection concentrate is indicated as a single agent or in combination for 1. the treatment of non small cell lung cancer (nsclc), and 2. the second line treatment of advanced breast cancer.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 110.8 mg (equivalent: vinorelbine, qty 80 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: vinorelbine pierre fabre is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.